Science
The Inconvenient Truth 142,000 People Proved — The Dream of Catching Cancer with a Drop of Blood Is Still Just a Dream
The NHS-Galleri trial with 142,000 participants failed its primary endpoint of reducing late-stage cancer diagnoses, with no mortality data presented. The U.S. signed MCED Medicare legislation despite zero FDA-approved tests, exposing a science-policy divide. At $949 per test, overdiagnosis risks and cost barriers challenge the premise that early detection saves lives.